Stay updated on Tucatinib Combo in HER2+ LMD Clinical Trial

Sign up to get notified when there's something new on the Tucatinib Combo in HER2+ LMD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib Combo in HER2+ LMD Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    Both screenshots show only minor UI/layout changes to the page header and navigation; the underlying study record content and history remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-10-27T21:10:08.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    - Added a government-operating-status notice and a link to official sources, indicating the page may have dynamic status information. - Updated version from v3.1.0 to v3.2.0, signaling a new release.
    Difference
    10%
    Check dated 2025-10-06T08:44:47.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    Changed the revision from v3.0.2 to v3.1.0, indicating a minor version update with no other content changes.
    Difference
    0.3%
    Check dated 2025-09-29T07:29:32.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Updated to Revision: v3.0.2 (replacing v3.0.1); removed the 'Back to Top' element.
    Difference
    0.6%
    Check dated 2025-09-14T23:11:52.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or important information.
    Difference
    0.6%
    Check dated 2025-09-07T19:47:19.000Z thumbnail image
  8. Check
    59 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of a facility name and location, as well as the early termination of a study due to FDA approval of tucatinib for metastatic HER2+ breast cancer. Several outdated study statuses and recruitment dates have also been removed.
    Difference
    35%
    Check dated 2025-08-31T12:38:35.000Z thumbnail image

Stay in the know with updates to Tucatinib Combo in HER2+ LMD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib Combo in HER2+ LMD Clinical Trial page.